| scholarly article | Q13442814 |
| P50 | author | Joseph R Calabrese | Q90776679 |
| P2093 | author name string | Antony Loebel | |
| Josephine Cucchiaro | |||
| Jane Xu | |||
| Robert Silva | |||
| Hans Kroger | |||
| Kaushik Sarma | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 169-177 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study | |
| P478 | volume | 171 |
| Q36253396 | A Lifetime Prevalence of Comorbidity Between Bipolar Affective Disorder and Anxiety Disorders: A Meta-analysis of 52 Interview-based Studies of Psychiatric Population |
| Q35607157 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression |
| Q37719513 | Acceleration of bone regeneration by activating Wnt/β-catenin signalling pathway via lithium released from lithium chloride/calcium phosphate cement in osteoporosis |
| Q60048075 | Antidepressants in bipolar depression: an enduring controversy |
| Q34475987 | Antipsychotics as antidepressants |
| Q39048593 | Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review |
| Q38297860 | Balancing benefits and harms of treatments for acute bipolar depression |
| Q38808576 | Bipolar depression: Managing patients with second generation antipsychotics |
| Q52656684 | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. |
| Q89665749 | Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better |
| Q38297855 | Current landscape, unmet needs, and future directions for treatment of bipolar depression |
| Q37279424 | Diagnosis and treatment of patients with bipolar disorder: A review for advanced practice nurses |
| Q36027225 | Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials |
| Q34676317 | Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology |
| Q26782989 | Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder |
| Q38507842 | Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat |
| Q34515834 | LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY |
| Q47124172 | Lithium chloride inhibits titanium particle-induced osteoclastogenesis by inhibiting the NF-κB pathway. |
| Q37675302 | Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment |
| Q38867652 | Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study |
| Q38904026 | Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis |
| Q36674291 | Lurasidone for the Treatment of Irritability Associated with Autistic Disorder |
| Q26796437 | Lurasidone for the treatment of bipolar depression: an evidence-based review |
| Q35544274 | Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies |
| Q38689883 | Lurasidone for the treatment of irritability and anger in autism spectrum disorders |
| Q33716263 | Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews |
| Q46498328 | Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. |
| Q38411188 | Lurasidone: a new treatment option for bipolar depression-a review |
| Q36444832 | Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression |
| Q38362255 | Lurasidone: a review of its use in adult patients with bipolar I depression |
| Q38795708 | Lurasidone: an antipsychotic with antidepressant effects in bipolar depression? |
| Q47623090 | Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders |
| Q27012673 | Management of bipolar I depression: clinical utility of lurasidone |
| Q38297863 | Managing the side effects associated with commonly used treatments for bipolar depression |
| Q64257508 | Modulation of anterior cingulate cortex reward and penalty signalling in medication-naive young-adult subjects with depressive symptoms following acute dose lurasidone |
| Q33960389 | PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression |
| Q47653213 | Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment |
| Q87505611 | Perils of Pragmatic Psychiatry: How We Can Do Better |
| Q89665746 | Personalized Pharmacotherapy for Bipolar Disorder: How to Tailor Findings From Randomized Trials to Individual Patient-Level Outcomes |
| Q38546598 | Pharmaceuticals that contain polycyclic hydrocarbon scaffolds. |
| Q26747670 | Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach |
| Q89665753 | Psychopharmacology and Experimental Therapeutics for Bipolar Depression |
| Q47953611 | Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension |
| Q35054265 | Results from an online survey of patient and caregiver perspectives on unmet needs in the treatment of bipolar disorder |
| Q26824365 | Review of evidence for use of antidepressants in bipolar depression |
| Q35862776 | Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders |
| Q100736090 | Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia: Results of a 2-Year, Open-Label Extension Study |
| Q38536939 | Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
| Q38697937 | The development of lurasidone for bipolar depression |
| Q39019778 | The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial |
| Q38208032 | The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder |
| Q94484818 | The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry |
| Q90700046 | Treatment of acute bipolar depression |
| Q38269372 | Treatment of bipolar depression: making sensible decisions |
| Q34823805 | Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges |
| Q89665761 | Working With a Patient With Bipolar I Disorder Who Is Experiencing Depression |
Search more.